TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2245947

Group type: EXPERIMENTAL
Intervention: Lactate gel (5 ml, pH 3.8) inserted into the vagina daily for 7 consecutive days, followed by prophylactic treatment 3 days monthly for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lactate gel
Number of subjects: 42
Study: 7354280

Group type: EXPERIMENTAL
Intervention: Referral form and return mailer
Number of subjects: 0
Study: 30091495

Group type: EXPERIMENTAL
Intervention: Modified developmental care bundle (environmental modifications, positioning and containment, oxygen supplementation, interaction and approach, cue‐based individual care)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Developmental care
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 14
Study: 29103415

Group type: EXPERIMENTAL
Intervention: Breathing exercises during the second stage of labor
Number of subjects: 250

Group type: COMPARATOR
Intervention: No breathing exercise training
Number of subjects: 250
Study: 26314696

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-flow O2
Number of subjects: 52
Study: 24576874

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21134503

Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 112

Group type: COMPARATOR
Intervention: COC
Number of subjects: 112
Study: 20003785

Group type: EXPERIMENTAL
Intervention: Suture group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Electro coagulation group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 61
Study: 17531279

Group type: EXPERIMENTAL
Intervention: Ivermectin low dose (25 microg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin standard dose (150 microg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin low dose (25 microg/kg) with second dose after 15 days
Number of subjects: 0
Study: 15448664

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage CSF (GM-CSF)
Number of subjects: 236

Group type: COMPARATOR
Intervention: No CSF (Control)
Number of subjects: 236
Study: 11157606

Group type: EXPERIMENTAL
Intervention: Prone Position (PP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine Position (SP)
Number of subjects: 10
Study: 9643622

Group type: EXPERIMENTAL
Intervention: Oral solution containing 80 mg sotalol and 20 mg cisapride
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sublingual tablet of 80 mg sotalol
Number of subjects: 7
Study: 7895388

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms twice a day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) (200 micrograms twice a day)
Number of subjects: 88
Study: 3309131

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 626

Group type: COMPARATOR
Intervention: methyldopa
Number of subjects: 626

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 626
Study: 30239676

Group type: EXPERIMENTAL
Intervention: Training and Support (TS) combined with Financial Reimbursement (FR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and Support (TS) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as Usual (Control)
Number of subjects: 0
Study: 28478850

Group type: EXPERIMENTAL
Intervention: Care bundles with chlorhexidine dressing (experimental group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Care bundles with advanced dressings (control group)
Number of subjects: 27
Study: 24337899

Group type: EXPERIMENTAL
Intervention: rTMS alone at 1 Hz frequency
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: rTMS alone at 10 Hz frequency
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: rTMS at 1 Hz frequency combined with paroxetine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: paroxetine alone
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo (sham rTMS)
Number of subjects: 75
Study: 23905373

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BHD) combined with Aspirin (ASP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clopidogrel and Aspirin (ASP)
Number of subjects: 84
Study: 21827677

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18303109

Group type: EXPERIMENTAL
Intervention: Reported alcohol use in the past year
Number of subjects: 4150

Group type: COMPARATOR
Intervention: No reported alcohol use in the past year
Number of subjects: 4150
Study: 16325846

Group type: EXPERIMENTAL
Intervention: Button-press go/no-go task with varying speed of stimulus presentation
Number of subjects: 120
Study: 12913785

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux (4 weeks)
Number of subjects: 0
Study: 11029516

Group type: EXPERIMENTAL
Intervention: Autologous platelet-derived wound healing factor (autologous PDWHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9360513

Group type: EXPERIMENTAL
Intervention: Low dose step-up regimen
Number of subjects: 37

Group type: COMPARATOR
Intervention: Step-down regimen
Number of subjects: 37
Study: 1535121

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 2981292

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with co-trimoxazole prophylaxis
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy without co-trimoxazole prophylaxis
Number of subjects: 103
Study: 30557160

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MVC + Emtricitabine (FTC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MVC + Tenofovir (TFV) disoproxil fumarate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TFV disoproxil fumarate + FTC
Number of subjects: 48

Group type: COMPARATOR
Intervention: MVC alone
Number of subjects: 48
Study: 29280868

Group type: EXPERIMENTAL
Intervention: Labiaplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 24
Study: 26166531

Group type: EXPERIMENTAL
Intervention: Psychological nursing performed by special nurses before, during and after the surgical procedure
Number of subjects: 70

Group type: COMPARATOR
Intervention: General knowledge of routine treatment and care (Control)
Number of subjects: 70
Study: 23333721

Group type: EXPERIMENTAL
Intervention: MRI group (n = 177)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (n = 86)
Number of subjects: 263
Study: 21315844

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: KCNH2 mutation
Number of subjects: 874

Group type: COMPARATOR
Intervention: QTc
Number of subjects: 874
Study: 19477803

Group type: EXPERIMENTAL
Intervention: Brief negotiation interviewing (BNI)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual education activities (Control)
Number of subjects: 212
Study: 16728967

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15078052

Group type: EXPERIMENTAL
Intervention: SOA randomized within subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOA blocked within subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: SOA manipulated between subjects
Number of subjects: 0
Study: 11531758

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and RT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study: 8172510

Group type: EXPERIMENTAL
Intervention: Instrumental straight-leg raising
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clinical straight-leg raising
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group of healthy volunteers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with aberrant muscle activity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with comparable electrical activity to controls
Number of subjects: 30
Study: 3215626

Group type: EXPERIMENTAL
Intervention: 2.5 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 MU rIFN-alpha/m2 body surface 3 times weekly i.m. during 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 24
Study: 29661382

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Manual Infusion
Number of subjects: 74
Study: 28895933

Group type: EXPERIMENTAL
Intervention: Higher protein intake (HP) group (n = 11) received a dietary plan with 1.2 g·kg‐1·day‐1 of protein
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal protein (NP) group (n = 12) ingested 0.8 g·kg‐1·day‐1 of protein (RDA recommendation)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups performed the same resistance training protocol, 3 times a week, for 10 weeks
Number of subjects: 23
Study: 25468401

Group type: EXPERIMENTAL
Intervention: BEST program (Internet-based lifestyle intervention)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 48
Study: 23234880

Group type: EXPERIMENTAL
Intervention: EHT 0202 (40 and 80 mg bid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22059476

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (LdAA) preoperatively (≤320 mg daily)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No low-dose acetylsalicylic acid (LdAA) preoperatively
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (LdAA) preoperatively
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Baseline cardiovascular and/or cerebrovascular disease
Number of subjects: 255
Study: 18279104

Group type: EXPERIMENTAL
Intervention: BAY 50‐4798
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 0
Study: 16598294

Group type: EXPERIMENTAL
Intervention: Pulse oximeter alarms set at 80% (low) and 96% (high), goal range 90‐95% (group 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pulse oximeter alarms set at 80% (low) and 94% (high), goal range 88 to 94% (group 2)
Number of subjects: 72
Study: 14721997

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (resynchronization therapy)
Number of subjects: 25
Study: 10763075

Group type: EXPERIMENTAL
Intervention: Shahal membership
Number of subjects: 1608
Study: 9765759

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with alkylating agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged adjuvant chemotherapy (busulfan or cytoxan daily for 2 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cyclophosphamide doxorubicin-cisplatin (CAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current chemotherapy regimens
Number of subjects: 0
Study: 8498417

Group type: EXPERIMENTAL
Intervention: Companionship from one of three volunteer labor companions
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 189
Study: 3320136

Group type: EXPERIMENTAL
Intervention: Family-patient teaching programme (twice a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no family-patient education)
Number of subjects: 30
Study: 31793395

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (stent-retriever and/or thromboaspiration)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 690
Study: 29410020

Group type: EXPERIMENTAL
Intervention: Olympus Exera III, 190-C
Number of subjects: 856

Group type: COMPARATOR
Intervention: Olympus 160/5-C
Number of subjects: 856
Study: 27493100

Group type: EXPERIMENTAL
Intervention: Probucol 250 mg/d
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg/d
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25795699

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF; lenograstim) 15 µg/kg body weight daily on days 1-5
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: G-CSF 15 µg/kg body weight daily on days 1-5 followed by leukapheresis, isolation and aliquoting of CD133+ cells, infusion of freshly isolated CD133+ cells immediately and frozen doses at days 30 and 60 (0.2×10(6) cells/kg for each of the three doses)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard conservative management
Number of subjects: 81
Study: 23912172

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibodies)
Number of subjects: 39
Study: 21929671

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18374755

Group type: EXPERIMENTAL
Intervention: Polyurethane cuffed endotracheal tube
Number of subjects: 134

Group type: COMPARATOR
Intervention: Polyvinyl chloride cuffed endotracheal tube
Number of subjects: 134
Study: 16835404

Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (6 sets of 10 repetition maximum squat)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Chronic resistance exercise training (24 weeks)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74
Study: 12637901

Group type: EXPERIMENTAL
Intervention: MARA (mandibular anterior repositioning appliance)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MARA
Number of subjects: 30
Study: 11064850

Group type: EXPERIMENTAL
Intervention: Exercise alone, details on dosage and duration not specified
Number of subjects: 0
Study: 8630721

Group type: EXPERIMENTAL
Intervention: Extended-release albuterol tablets (4 mg twice daily, increasing up to 12 mg q 12h)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 8161670

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.d.s.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 40
Study: 3948141

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (Roferon‐A), 36 X 10(6)U intramuscularly 3 times weekly
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (Roferon‐A) in combination with vinblastine, 0.10‐0.15 mg/kg intravenously every 2 to 3 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (Roferon‐A)
Number of subjects: 20
Study: 31605929

Group type: COMPARATOR
Intervention: Ctrl (no pigmentation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Brush 1× (brushing on 1 application)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Brush 3× (brushing on 3 applications)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Immer 2min (immersion for 2 minutes)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Immer 4min (immersion for 4 minutes)
Number of subjects: 75
Study: 30527204

Group type: EXPERIMENTAL
Intervention: 4.8 French ureteral JJ stents (group 1)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 6 French ureteral JJ stents (group 2)
Number of subjects: 188

Group type: COMPARATOR
Intervention: No stent insertion (group 3)
Number of subjects: 188
Study: 26275686

Group type: EXPERIMENTAL
Intervention: Cyclosporine-A 0.05% ophthalmic emulsion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carboxymethylcellulose 0.5% (CMC) eye drops
Number of subjects: 30
Study: 24901425

Group type: EXPERIMENTAL
Intervention: Scleral buckling surgery (SBS) - cerclage + cryopexy + subretinal fluid drainage (SRD) + SF6 or air (n=28 eyes)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV) - PPV + laser photocoagulation + C3F8
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of SBS and PPV
Number of subjects: 44

Group type: COMPARATOR
Intervention: Operated eye vs. fellow eye
Number of subjects: 44
Study: 22488662

Group type: EXPERIMENTAL
Intervention: Cohorts 1 + 2 (n = 68) with standard induction therapy
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cohort 3 (n = 141) with modified induction therapy (prednisone 40 mg/m(2)/day, short infusion daunorubicin 30 minutes)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cohorts 1 + 2 (n = 68) among infants ≤90 days of age at diagnosis
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cohort 3 (n = 141) among infants ≤90 days of age at diagnosis
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cohorts 1 + 2 (n = 68) among infants >90 days of age at diagnosis
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cohort 3 (n = 141) among infants >90 days of age at diagnosis
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cohorts 1 + 2 (n = 68)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cohort 3 (n = 141)
Number of subjects: 209
Study: 20007756

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS) 135 mg three times daily for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS)
Number of subjects: 62
Study: 18347912

Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study: 15881483

Group type: EXPERIMENTAL
Intervention: Freeze-dried r-hFSH (300 IU)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Liquid r-hFSH (300 IU)
Number of subjects: 39
Study: 12605350

Group type: EXPERIMENTAL
Intervention: Agnus castus (AC: 120 ‐ 480 mg/die) for 14 days
Number of subjects: 20
Study: 10529325

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265
Study: 9101801

Group type: EXPERIMENTAL
Intervention: Immediate necrectomy (within the first 3 days post-trauma)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Early necrectomy (from the fourth post-traumatic day)
Number of subjects: 66
Study: 1854374

Group type: EXPERIMENTAL
Intervention: Alcohol 0.75g/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alcohol 0.25g/kg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 6151504

Group type: EXPERIMENTAL
Intervention: Propranolol (1-8 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pindolol (0.1-0.8 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single i.v. Propranolol (8 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single i.v. Pindolol (0.8 mg)
Number of subjects: 20
Study: 30707882

Group type: EXPERIMENTAL
Intervention: Self-made pressure-resistant cap cotton cover
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional nursing with traditional hydrocolloid dressings
Number of subjects: 50
Study: 29089093

Group type: EXPERIMENTAL
Intervention: Ganglion plexus ablation (n = 101)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (n = 100)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ganglion plexus ablation
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 27448832

Group type: EXPERIMENTAL
Intervention: Fundus Autofluorescence (FAF) images
Number of subjects: 2202

Group type: COMPARATOR
Intervention: Color photographs
Number of subjects: 2202
Study: 24231555

Group type: EXPERIMENTAL
Intervention: Repeated-sprint training (RST) 2 d/wk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined RST and squat resistance training with superimposed vibrations (RS+ST) 1 d/wk
Number of subjects: 20
Study: 22414094

Group type: EXPERIMENTAL
Intervention: Blunt suture needles
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sharp suture needles
Number of subjects: 300
Study: 20190601

Group type: EXPERIMENTAL
Intervention: Landiolol (treatment L)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (treatment C)
Number of subjects: 15
Study: 18471410

Group type: EXPERIMENTAL
Intervention: Low-protein diet plus alpha-keto acid
Number of subjects: 89

Group type: COMPARATOR
Intervention: Routine-protein diet
Number of subjects: 89

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 89
Study: 16274095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3431
Study: 11827919

Group type: EXPERIMENTAL
Intervention: Combination therapy (warfarin plus aspirin)
Number of subjects: 5059

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 5059
Study: 10406248

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.01 mg/kg, maximum 1.0 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (intravenous normal saline)
Number of subjects: 29
Study: 7555258

Group type: EXPERIMENTAL
Intervention: oral low-dose acyclovir (600-800 mg per day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 66
Study: 1701507

Group type: EXPERIMENTAL
Intervention: polyvinylpyrrolidone‐iodine (Betaisodona)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: exogenous interferon alpha with polyvinylpyrrolidone‐iodo‐drops or trifluorothymidine‐drops
Number of subjects: 150

Group type: COMPARATOR
Intervention: vasoconstrictor
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: topical corticosteroids in combination with antibiotics
Number of subjects: 150
Study: 7004478

Group type: EXPERIMENTAL
Intervention: Ganda 1.02 (guanethidine 1% and adrenaline 0.2% mixture)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Adrenaline 1% (Simplene)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pilocarpine 1% (Sno-Pilo)
Number of subjects: 77
Study: 31631361

Group type: EXPERIMENTAL
Intervention: Three fractional ablative CO2 laser treatments at 8‐week intervals
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (untreated areas)
Number of subjects: 19